GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (WBO:UCB) » Definitions » Debt-to-Revenue

UCB (WBO:UCB) Debt-to-Revenue : 0.54 (As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is UCB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

UCB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €54 Mil. UCB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €2,984 Mil. UCB's annualized Revenue for the quarter that ended in Jun. 2024 was €5,582 Mil. UCB's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 was 0.54.


UCB Debt-to-Revenue Historical Data

The historical data trend for UCB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Debt-to-Revenue Chart

UCB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.51 0.37 0.53 0.58

UCB Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.56 0.56 0.57 0.54

Competitive Comparison of UCB's Debt-to-Revenue

For the Biotechnology subindustry, UCB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UCB's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UCB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where UCB's Debt-to-Revenue falls into.



UCB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

UCB's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(42 + 2996) / 5252
=0.58

UCB's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(54 + 2984) / 5582
=0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2024) Revenue data.


UCB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of UCB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


UCB Business Description

Address
Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).